HC Wainwright reiterated their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $17.00 price objective on the stock.
Other equities analysts have also recently issued research reports about the company. JMP Securities reissued a market outperform rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, April 18th. Wedbush reissued an outperform rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, July 11th.
Check Out Our Latest Analysis on Vigil Neuroscience
Vigil Neuroscience Stock Performance
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.10. As a group, analysts predict that Vigil Neuroscience will post -2.1 EPS for the current fiscal year.
Hedge Funds Weigh In On Vigil Neuroscience
A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio purchased a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is owned by institutional investors and hedge funds.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
- Five stocks we like better than Vigil Neuroscience
- How to Invest in Blue Chip Stocks
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.